2016 American Transplant Congress
VDJ Immune Repertoire Sequencing Predicts Patients at Risk of Alloimmune Injury.
1Surgery and Bioinformatics, UCSF, San Francisco, CA; 2Genetics, Stanford University, Palo Alto, CA.
Background: The complex repertoire of immune receptors generated by B cells enables allo-recognition in the context of transplantation across HLA barriers, and is a major…2016 American Transplant Congress
HLA Antibody Clonality and Epitopes Dictate Complement Activation.
Background: Alloimmunization results in production of polyclonal donor specific antibodies (DSA) against human leukocyte antigens (HLA), which mediate endothelial cell activation, leukocyte recruitment, and complement…2016 American Transplant Congress
Enabled PRA and Precision PRA: Alternatives to cPRA as Desensitization Trial Endpoints.
U of Cincinnati, Cincinnati; Mayo Clinic Scottsdale, Scottsdale.
Transplant (Transplant) rate is an optimal endpoint in desensitization (DS) trials in HLA sensitized Txp candidates, however, for waitlisted Txp candidates, wait time heterogeneity compromises…2016 American Transplant Congress
Long-Term Follow-Up of Renal Transplant Recipients (RTR) Treated with IVIG for De Novo Donor Specific Antibodies (DSA).
1Houston Methodist Hospital, Houston, TX; 2Kansas University Medical Center, Kansas City, KS.
Intravenous immune globulin (IVIG) may be beneficial for pre-emptive treatment of de novo DSA in RTR without biopsy-proven acute rejection (AR). Herein, we present long-term…2016 American Transplant Congress
MHC/HLA-Specific IgE in Allotransplantation.
Background: Donor-specific antibodies (DSA) are recognized as important factors in determining outcome in renal transplantation.Typically DSAs of the IgG isotype are measured, but little is…2015 American Transplant Congress
Natural History of Anti- Human Leukocyte Antigen Antibodies After Hear Transplant
Cedars-Sinai Heart Institute, Los Angeles, CA.
Purpose: The natural history of the production of circulating antibodies has not yet been clearly established. Recent technology has allowed for the improved detection of…2015 American Transplant Congress
The Use of Eculizumab to Treat the Highly Sensitized Patient Awaiting Heart Transplant
Cedars-Sinai Heart Institute, Los Angeles, CA.
Purpose: Highly sensitized patients (pts) awaiting heart transplantation remain a significant challenge due to prolonged often prohibitive wait times for suitable organs and increased rejection…2015 American Transplant Congress
The Molecular Landscape of Atrophy-Fibrosis in Human Kidney Transplants: The Dominant Role of Acute Parenchymal Injury
University of Alberta, Edmonton, Canada.
We studied the effect of time post-transplant on atrophy-fibrosis (AF) and molecular associations with AF in 703 kidney transplant indication biopsies (bx) 3 days to…2015 American Transplant Congress
Serum Creatinine Is Most Predictive of Graft Loss in Late Antibody Mediated Rejection
Comprehensive Transplant Institute, University of Alabama at Birmingham, Birmingham, AL.
Development of acute antibody mediated rejection (AMR) is associated with graft loss and can occur both early (< 3 months) and late (> 3 months)…2015 American Transplant Congress
Plasmapharesis, Intravenous Immunoglobulin and Rituximab Successfully Treat Recurrent Progressive Familial Intrahepatic Cholestasis Type 2 (PFIC-2) After Liver Transplantation
Background:Allo-immune mediated BSEP dysfunction may occur after liver transplantation in PFIC2 patients leading to a PFIC2 like phenotype. The IgG antibodies are reactive toward a…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- Next Page »